Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer, covers the month of September 2021. The report, dated September 1, 2021, consists solely of a press release attached as Exhibit 99.1 and incorporated by reference. The filing is signed by Spiros Jamas, Sc.D., the Chief Executive Officer and Director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As this report incorporates only a press release, it does not contain audited financial statements or detailed financial data tables.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The document serves as a vehicle to distribute a press release rather than a financial performance report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The content of the referenced press release (Exhibit 99.1) is not included in the provided text, preventing a summary of these qualitative factors.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K incorporating a press release dated September 1, 2021.
- No financial data or operational metrics are present in the provided text.
- Investors must review the attached Exhibit 99.1 (the press release) to understand the specific corporate announcement triggering this filing.
- The registrant files annual reports on Form 20-F.